Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
80M
-
Number of holders
-
238
-
Total 13F shares, excl. options
-
86.2M
-
Shares change
-
+12.1M
-
Total reported value, excl. options
-
$3.5B
-
Value change
-
+$531M
-
Put/Call ratio
-
0.78
-
Number of buys
-
166
-
Number of sells
-
-74
-
Price
-
$40.48
Significant Holders of Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) as of Q1 2025
288 filings reported holding AKRO - Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q1 2025.
Akero Therapeutics, Inc. - Common Stock, par value $0.0001 per share (AKRO) has 238 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 86.2M shares
.
Largest 10 shareholders include RTW INVESTMENTS, LP (7.42M shares), JANUS HENDERSON GROUP PLC (7.07M shares), BlackRock, Inc. (6.26M shares), WELLINGTON MANAGEMENT GROUP LLP (5.94M shares), GENERAL ATLANTIC, L.P. (5.23M shares), PRICE T ROWE ASSOCIATES INC /MD/ (4.82M shares), VANGUARD GROUP INC (4.23M shares), Deep Track Capital, LP (3.21M shares), STATE STREET CORP (2.49M shares), and UBS Group AG (2.16M shares).
This table shows the top 238 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.